MM is taking a loss on Resmed (RMD), the quarterly result was below expectations and recent price action has been poor.
MM is selling RMD in the Active Growth Portfolio, taking a loss around $26.50
Add To Hit List
We are buying ProMedicus (PME) for leverage to the software and technology rebound, on the back of a string of quality contract wins.
MM is buying PME in the Active Growth Portfolio, targeting a 4% weighting around $145
Add To Hit List
